Sep 30, 2025 07:38AM Maxim Group Upgrades Adial Pharmaceuticals Inc (ADIL) to Buy, PT $1.50

Sep 3, 2025 08:30AM Adial Pharmaceuticals gets 180-day extension to meet NASDAQ price rule

Aug 20, 2025 08:31AM Adial Pharmaceuticals welcomes senate support for AUD trial endpoints

Aug 6, 2025 08:02AM Adial Pharmaceuticals completes FDA meeting for AD04 phase 3 trial

Jul 9, 2025 08:32AM Adial Pharmaceuticals files patent application for AD04 drug through 2045

Jun 25, 2025 08:35AM Adial Pharmaceuticals (ADIL) partners with Cambrex and Thermo Fischer (TMO) for AD04

Jun 17, 2025 08:02AM Adial Pharmaceuticals (ADIL) Prices $3.6M Share Offering at $0.35/sh

Jun 11, 2025 08:01AM Adial Pharmaceuticals (ADIL) Advances Toward Phase 3 Development for AD04

May 30, 2025 04:14PM Adial Pharmaceuticals (ADIL) Files for 6.73M Share Offering by Selling Stockholders

May 8, 2025 08:30AM Adial Pharmaceuticals (ADIL) Granted End of Phase 2 Meeting from the FDDA

May 2, 2025 11:49AM Adial Pharmaceuticals (ADIL) Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

May 1, 2025 08:32AM Adial Pharmaceuticals (ADIL) Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Mar 4, 2025 09:59AM Rodman & Renshaw Reiterates Buy Rating on Adial Pharmaceuticals Inc (ADIL)

Feb 25, 2025 09:01AM Adial Pharmaceuticals (ADIL) Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Feb 19, 2025 09:02AM Adial Pharmaceuticals (ADIL) Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Feb 12, 2025 09:01AM Adial Pharmaceuticals (ADIL) Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Jan 29, 2025 09:02AM Adial Pharmaceuticals (ADIL) Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Dec 3, 2024 08:31AM Adial Pharmaceuticals (ADIL) Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Nov 14, 2024 08:40AM Adial Pharmaceuticals (ADIL) Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Nov 14, 2024 06:38AM Rodman & Renshaw Starts Adial Pharmaceuticals Inc (ADIL) at Buy

Nov 5, 2024 08:30AM Adial Pharmaceuticals (ADIL)Appoints Vinay Shah as CFO

Oct 17, 2024 09:03AM Adial Pharmaceuticals (ADIL) Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment

Sep 19, 2024 08:31AM Adial Pharmaceuticals (ADIL) Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Aug 13, 2024 09:03AM Adial Pharmaceuticals (ADIL) Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

Jul 31, 2024 08:32AM Adial Pharmaceuticals (ADIL) Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044